gip/glp-1 receptor agonist Emerging Role of Dual GLP-1 and GIP Agonists | DMSO Dual and Triple Gut Peptide
Description
RothCLPerezFAWhitlockKBElfersCYanovskiJAShoemakerAHet alA phase 3 randomized clinical trial using a once-weekly glucagon-like peptide-1 receptor agonist in adolescents and young adults with hypothalamic obesity
Schinzari F, Armuzzi A, De Pascalis B, Mores N, Tesauro M, Melina D, et al
It is even possible that the insulin-stimulating, glucagon-suppressing effects of the peptide or a more active synthetic analogue may be useful in the treatment of non-insulin-dependent diabetes, in which both impaired insulin release in response to glucose and persistent hyperglucagonemia are thought to be key pathophysiological abnormalities' (Kreymann, Ghattei, Williams, Bloom)
WHO (2025)
The experimental drug has shown particular promise as a treatment for obesity
Hou S, Li C, Huan Y, Liu S, Liu Q, Sun S, et al
